propafenone has been researched along with Coronary Disease in 36 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety and efficacy of amiodarone and propafenone in converting atrial fibrillation or flutter after cardiac surgery were compared in a randomized double-blind trial." | 9.08 | Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. ( Cappiello, E; Di Biasi, P; Mangini, A; Paje, A; Santoli, C; Scrofani, R, 1995) |
| "Multivariate regression analysis of spontaneous arrhythmia variability and of different clinical variables to determine the short and long-term efficacy and safety of propafenone." | 9.07 | Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms. ( Furtwängler, A; Geibel, A; Hohnloser, S; Just, H; Meinertz, T; Olschewski, M; Zehender, M, 1992) |
| "In 12 patients with coronary artery disease, 11 of them with previous myocardial infarction, the antiarrhythmic effects of orally administered flecainide (F." | 9.05 | [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)]. ( Fabry, E; Klempt, HW; Nayebagha, A, 1982) |
| "The efficacy of propafenone hydrochloride, a new antiarrhythmic agent, was evaluated in the treatment of chronic stable ventricular arrhythmias." | 9.05 | Oral propafenone in the suppression of chronic stable ventricular arrhythmias. ( Kawalsky, DL; Myburgh, DP; Pincus, DR; Schamroth, CL; Schamroth, L; Scholtz, ME, 1985) |
| "To determine the electrophysiological properties of oral propafenone, 50 patients (39 male and 11 female, aged 31 to 80 years) with sustained ventricular tachycardia or ventricular fibrillation underwent serial electrophysiological drug testing, using propafenone (750 to 900 mg daily) as the anti-arrhythmic regimen of first choice." | 7.68 | Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation. ( Frohner, K; Hief, C; Podczeck, A; Steinbach, KK; Stix, G, 1991) |
| "A case of pulmonary fibrosis attributed to amiodarone was studied immunologically and morphologically." | 7.67 | Amiodarone-associated pulmonary fibrosis. Evidence of an immunologically mediated mechanism. ( Bell, R; Eudy, S; Fan, K; Fullenwider, J, 1987) |
| "The efficacy of Propafenone to prevent exercise-induced ventricular arrhythmias (EIVA) has been studied in eleven patients affected by ischemic heart disease." | 7.67 | [Effects of propafenone on arrhythmias induced by exertion in patients with ischemic cardiopathy]. ( Arrigo, F; Giannetto, M; Luzza, F; Oreto, G; Patané, S; Virga, T, 1987) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 7.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "The safety and efficacy of amiodarone and propafenone in converting atrial fibrillation or flutter after cardiac surgery were compared in a randomized double-blind trial." | 5.08 | Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation. ( Cappiello, E; Di Biasi, P; Mangini, A; Paje, A; Santoli, C; Scrofani, R, 1995) |
| "Multivariate regression analysis of spontaneous arrhythmia variability and of different clinical variables to determine the short and long-term efficacy and safety of propafenone." | 5.07 | Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms. ( Furtwängler, A; Geibel, A; Hohnloser, S; Just, H; Meinertz, T; Olschewski, M; Zehender, M, 1992) |
| "In 12 patients with coronary artery disease, 11 of them with previous myocardial infarction, the antiarrhythmic effects of orally administered flecainide (F." | 5.05 | [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)]. ( Fabry, E; Klempt, HW; Nayebagha, A, 1982) |
| "The efficacy of propafenone hydrochloride, a new antiarrhythmic agent, was evaluated in the treatment of chronic stable ventricular arrhythmias." | 5.05 | Oral propafenone in the suppression of chronic stable ventricular arrhythmias. ( Kawalsky, DL; Myburgh, DP; Pincus, DR; Schamroth, CL; Schamroth, L; Scholtz, ME, 1985) |
| "This retrospective case series study sought to describe the safety and clinical effectiveness of propafenone for the control of arrhythmias in children with and without CHD or cardiomyopathy." | 4.12 | Electrophysiological effects and clinical utility of propafenone in children. ( Ferns, SJ; Gehi, AK; Hudak, ML; McKenzie, K; Singh, M, 2022) |
| "To determine the electrophysiological properties of oral propafenone, 50 patients (39 male and 11 female, aged 31 to 80 years) with sustained ventricular tachycardia or ventricular fibrillation underwent serial electrophysiological drug testing, using propafenone (750 to 900 mg daily) as the anti-arrhythmic regimen of first choice." | 3.68 | Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation. ( Frohner, K; Hief, C; Podczeck, A; Steinbach, KK; Stix, G, 1991) |
| "A case of pulmonary fibrosis attributed to amiodarone was studied immunologically and morphologically." | 3.67 | Amiodarone-associated pulmonary fibrosis. Evidence of an immunologically mediated mechanism. ( Bell, R; Eudy, S; Fan, K; Fullenwider, J, 1987) |
| "The efficacy of Propafenone to prevent exercise-induced ventricular arrhythmias (EIVA) has been studied in eleven patients affected by ischemic heart disease." | 3.67 | [Effects of propafenone on arrhythmias induced by exertion in patients with ischemic cardiopathy]. ( Arrigo, F; Giannetto, M; Luzza, F; Oreto, G; Patané, S; Virga, T, 1987) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 3.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "Diprafenone (D) is a new class I c antiarrhythmic agent, structurally similar to propafenone." | 1.27 | Use of diprafenone, a new potent propafenone-analogue, in acute experimental myocardial ischaemia and infarction. ( Bender, F; Gülker, H; Haverkamp, W; Hindricks, G; Thale, J, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (61.11) | 18.7374 |
| 1990's | 11 (30.56) | 18.2507 |
| 2000's | 2 (5.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, M | 1 |
| McKenzie, K | 1 |
| Hudak, ML | 1 |
| Gehi, AK | 1 |
| Ferns, SJ | 1 |
| Klempt, HW | 1 |
| Nayebagha, A | 1 |
| Fabry, E | 1 |
| Lüderitz, B | 2 |
| Zeiler, RH | 1 |
| Gough, WB | 1 |
| El-Sherif, N | 1 |
| Etoh, Y | 1 |
| Nakazawa, M | 1 |
| Imai, S | 1 |
| Hopf, R | 1 |
| Becker, HJ | 1 |
| Kober, G | 1 |
| Dowinsky, S | 1 |
| Kaltenbach, M | 1 |
| Wester, HA | 1 |
| Mouselimis, N | 1 |
| Karagueuzian, HS | 1 |
| Fujimoto, T | 1 |
| Katoh, T | 1 |
| Peter, T | 1 |
| McCullen, A | 1 |
| Mandel, WJ | 1 |
| Sosa, E | 1 |
| Pileggi, F | 1 |
| Grupi, C | 1 |
| Garcia, D | 1 |
| Vanzini, P | 1 |
| Décourt, LV | 1 |
| Merrick, AF | 1 |
| Odom, NJ | 1 |
| Keenan, DJ | 1 |
| Grotte, GJ | 1 |
| Di Biasi, P | 1 |
| Scrofani, R | 1 |
| Paje, A | 1 |
| Cappiello, E | 1 |
| Mangini, A | 1 |
| Santoli, C | 1 |
| Dobrotvorskaia, TE | 1 |
| Koroleva, ON | 1 |
| Gordina, OV | 1 |
| Marakanova, AV | 1 |
| Wang, X | 1 |
| Zhang, J | 1 |
| Shi, D | 1 |
| Zhou, G | 1 |
| Aggarwal, A | 2 |
| Sandrikov, VA | 1 |
| Ol'binskaia, LI | 1 |
| Demurov, EA | 1 |
| Sadovnikov, VI | 1 |
| Mikhailov, IuN | 1 |
| Winslow, E | 1 |
| Mason, R | 1 |
| Zehender, M | 1 |
| Hohnloser, S | 1 |
| Geibel, A | 1 |
| Furtwängler, A | 1 |
| Olschewski, M | 1 |
| Meinertz, T | 1 |
| Just, H | 1 |
| Németh, M | 1 |
| Papp, JG | 1 |
| Podczeck, A | 1 |
| Frohner, K | 1 |
| Hief, C | 1 |
| Stix, G | 1 |
| Steinbach, KK | 1 |
| Faucon, G | 2 |
| Aupetit, JF | 2 |
| Gerentes-Chassagne, I | 2 |
| Loufoua-Moundanga, J | 2 |
| Larbre, JP | 1 |
| Timour, Q | 2 |
| Kioueh, I | 1 |
| Lecky, BR | 1 |
| Weir, D | 1 |
| Chong, E | 1 |
| Liusov, VA | 2 |
| Borodkin, VV | 2 |
| Volov, NA | 1 |
| Dudaev, VA | 2 |
| Rudakov, AV | 1 |
| Fierro, B | 1 |
| Castiglione, MG | 1 |
| Salemi, G | 1 |
| Savettieri, G | 1 |
| Fan, K | 1 |
| Bell, R | 1 |
| Eudy, S | 1 |
| Fullenwider, J | 1 |
| Thale, J | 2 |
| Gülker, H | 2 |
| Hindricks, G | 1 |
| Haverkamp, W | 1 |
| Bender, F | 2 |
| Patané, S | 1 |
| Virga, T | 1 |
| Giannetto, M | 1 |
| Luzza, F | 1 |
| Oreto, G | 1 |
| Arrigo, F | 1 |
| Fernandez, F | 1 |
| Boyibanga, J | 1 |
| Vrancea, F | 1 |
| Maarek-Charbit, M | 1 |
| Genet, P | 1 |
| Gay, J | 1 |
| Schwartz, PJ | 1 |
| Vanoli, E | 1 |
| Terrosu, P | 1 |
| Ibba, GV | 1 |
| Franceschino, V | 1 |
| Contini, GM | 1 |
| Delpini, A | 1 |
| Manz, M | 1 |
| Beermann, J | 1 |
| Gerckens, U | 1 |
| Schamroth, L | 1 |
| Myburgh, DP | 1 |
| Schamroth, CL | 1 |
| Scholtz, ME | 1 |
| Pincus, DR | 1 |
| Kawalsky, DL | 1 |
| Alboni, P | 1 |
| Pirani, R | 1 |
| Paparella, N | 1 |
| Candini, GC | 1 |
| Tomasi, AM | 1 |
| Masoni, A | 1 |
| Olbing, B | 1 |
| Heuer, H | 1 |
| Frenking, B | 1 |
1 review available for propafenone and Coronary Disease
| Article | Year |
|---|---|
[Treatment of angina pectoris with calcium antagonists].
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Diltiazem; Drug Therapy, Combination; E | 1982 |
8 trials available for propafenone and Coronary Disease
| Article | Year |
|---|---|
[Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Coronary Disease; Electrocardiogr | 1982 |
[The effect of anti-arrhythmic drugs on myocardial function (author's transl)].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Coronary Disease; Depression, Chemical; Disopyramide; Echocardi | 1982 |
Comparison of propafenone to atenolol for the prophylaxis of postcardiotomy supraventricular tachyarrhythmias: a prospective trial.
Topics: Adult; Aged; Atenolol; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; D | 1995 |
Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Coronary Disease; Dos | 1995 |
[Clinical trial of propafenone (rytmonorm) in arrhythmia of patients with ischemic heart disease)].
Topics: Angina Pectoris; Angina, Unstable; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Coronary Di | 1996 |
Clinical observation on 84 cases of ventricular premature beat with deficiency syndrome treated by qi lu tang.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Coronary Disease; Drugs, Chinese Herbal; Female; Humans; Male; | 1998 |
Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms.
Topics: Adult; Age Factors; Aged; Arrhythmias, Cardiac; Coronary Disease; Drug Administration Schedule; Elec | 1992 |
Oral propafenone in the suppression of chronic stable ventricular arrhythmias.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; | 1985 |
27 other studies available for propafenone and Coronary Disease
| Article | Year |
|---|---|
Electrophysiological effects and clinical utility of propafenone in children.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Child, Preschool; Coronary Disease; | 2022 |
[Drug therapy of arrhythmia in coronary cardiopathy].
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneacetamides; Cardiac Comp | 1983 |
Electrophysiologic effects of propafenone on canine ischemic cardiac cells.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Dogs; El | 1984 |
Effects of etafenone on myocardial energy metabolism as studied by an organ redoximeter and biochemical analyses.
Topics: Animals; Coronary Circulation; Coronary Disease; Energy Metabolism; Female; Guinea Pigs; Heart; Hear | 1984 |
Suppression of ventricular arrhythmias by propafenone, a new antiarrhythmic agent, during acute myocardial infarction in the conscious dog. A comparative study with lidocaine.
Topics: Animals; Arterial Occlusive Diseases; Coronary Disease; Depression, Chemical; Diastole; Dogs; Electr | 1982 |
[Electrophysiological properties of propafenon evaluated by the technic of the bundle of His electrogram].
Topics: Adult; Aged; Bundle of His; Coronary Disease; Electrophysiology; Female; Heart Conduction System; He | 1981 |
Prevention of sudden death in patients with coronary artery disease.
Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Disease; Death, Sudden, Cardiac; Defibr | 2000 |
Amiodarone to prevent recurrence of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Humans; Hypertrophy, Left | 2000 |
[Effect of baxacor on the hemodynamics and contractile function of the myocardium in acute ischemia (an experimental study)].
Topics: Acute Disease; Animals; Coronary Disease; Dogs; Female; Heart Rate; Hemodynamics; Male; Myocardial C | 1978 |
Comparative hemodynamic effects of Org 7797, flecainide, and propafenone in anesthetized pigs with developing myocardial infarcts.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Dose-Response Relationship, Drug; Estrenes; Femal | 1992 |
Effects of simulated ischaemia on the electrical activity of ventricular myocardium in the presence of antiarrhythmic drugs.
Topics: Action Potentials; Animals; Coronary Disease; Electric Stimulation; Female; Heart; Heart Conduction | 1991 |
Acute and long-term efficacy of propafenone in patients with sustained ventricular tachyarrhythmias: assessment with programmed ventricular stimulation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Coronary Disease; Drug Evaluation; Electric St | 1991 |
[Arrhythmogenic risk of antiarrhythmic drugs: study with class Ic drugs during myocardial ischemia].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Coronary Disease; | 1991 |
Class Ic antiarrhythmic drugs and myocardial ischaemia: study in the pig heart in situ.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Blood Pressure; Coronary Disease; Coronary Vesse | 1991 |
Exacerbation of myasthenia by propafenone.
Topics: Aged; Coronary Disease; Heart Ventricles; Humans; Male; Myasthenia Gravis; Neurologic Examination; P | 1991 |
[Use of prolecofen in the treatment of arrhythmia in patients with ischemic heart disease].
Topics: Adult; Aged; Atrial Fibrillation; Cardiac Complexes, Premature; Coronary Disease; Female; Hemostasis | 1989 |
[Changes in thrombocyte-vascular hemostasis and cyclic nucleotide levels after anti-arrhythmia therapy in patients with ischemic heart disease].
Topics: Adult; Aged; Arrhythmias, Cardiac; Coronary Disease; Disopyramide; Female; Humans; Male; Mexiletine; | 1989 |
Myasthenia-like syndrome induced by cardiovascular agents. Report of a case.
Topics: Aged; Cardenolides; Coronary Disease; Drug Therapy, Combination; Humans; Male; Myasthenia Gravis; Ne | 1987 |
Amiodarone-associated pulmonary fibrosis. Evidence of an immunologically mediated mechanism.
Topics: Amiodarone; Coronary Disease; Drug Therapy, Combination; Electrophoresis, Polyacrylamide Gel; Fluore | 1987 |
Use of diprafenone, a new potent propafenone-analogue, in acute experimental myocardial ischaemia and infarction.
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Chemical Phenomena; Chemis | 1987 |
[Effects of propafenone on arrhythmias induced by exertion in patients with ischemic cardiopathy].
Topics: Aged; Arrhythmias, Cardiac; Coronary Disease; Electrocardiography; Heart Ventricles; Humans; Male; M | 1987 |
[Effects on the systemic and coronary circulation of a new IC-group anti-arrhythmia agent: propafenone. Hemodynamic study of 10 patients in the basal state and under auricular electric stimulation, before and after the intravenous injection of propafenone
Topics: Adult; Anti-Arrhythmia Agents; Coronary Circulation; Coronary Disease; Electric Stimulation; Female; | 1986 |
An experimental approach to the choice of antiarrhythmic therapy.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cats; Coronary Disease; Diltiazem | 1986 |
[Effects of propafenone on coronary and systemic hemodynamics].
Topics: Adult; Cardiac Catheterization; Coronary Circulation; Coronary Disease; Coronary Vessels; Heart Rate | 1986 |
[Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle of His; Cardiomyopathy, Dilated; Coronary Diseas | 1986 |
A method for evaluating different modes of action of an antiarrhythmic drug in man. The effects of propafenone on sinus nodal functions.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atropine; Autonomic Nervous S | 1985 |
Assessment of the antiarrhythmic profile of the new class I agent diprafenone.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Dogs; Electrocardiography; Female; Heart Conducti | 1985 |